Placental-type plasminogen activator inhibitor in preeclampsia.
The present cross-sectional study in patients with preeclampsia and gestational hypertension and in gestational age-matched controls was undertaken to investigate further the fibrinolytic system in these conditions. In preeclampsia we observed increased levels of total plasminogen activator inhibitor (p less than 0.001) but low levels of placental-type plasminogen activator inhibitor (p less than 0.05) compared with controls. The levels of placental-type plasminogen activator inhibitor were even more reduced (p less than 0.002) in pregnancies with a poor fetal outcome. It is concluded that placental-type plasminogen activator inhibitor does not contribute to the increased levels of total plasminogen activator inhibitor activity in preeclampsia. Placental-type plasminogen activator inhibitor levels correlated significantly with birth weight and placenta weight and may therefore reflect placental function.
D000328:Adult; D005260:Female; D005313:Fetal Death; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006801:Humans; D006973:Hypertension / Q000097:blood; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors*; D015849:Plasminogen Inactivators; D010976:Platelet Count; D011225:Pre-Eclampsia / Q000097:blood*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000097:blood; D011257:Pregnancy Proteins / Q000097:blood*; D010959:Tissue Plasminogen Activator / Q000097:blood
D005338:Fibrin Fibrinogen Degradation Products; D015849:Plasminogen Inactivators; D011257:Pregnancy Proteins; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator